共 36 条
[1]
Domschke K(2010)Imaging genetics of anxiety disorders NeuroImage 53 822-831
[2]
Dannlowski U(2014)Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options Pharmacotherapy 34 166-184
[3]
Drozda K(2009)The intersection of pharmacology, imaging, and genetics in the development of personalized medicine Dialogues Clin Neurosci 11 363-376
[4]
Müller DJ(2014)Making sense of deep sequencing Int J Neuropsychopharmacol 17 1717-1725
[5]
Bishop JR(2007)Personalized medicine—some thoughts McGill J Med 10 58-5989
[6]
Gerretsen P(2012)The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction Curr Pharm Des 18 5976-404
[7]
Müller DJ(2014)Epigenetic alterations in depression and antidepressant treatment Dialogues Clin Neurosci 16 395-571
[8]
Tiwari A(2013)Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic Int Rev Psychiatry 25 554-1746
[9]
Mamo D(2013)Challenging sequential approach to treatment resistant depression: cost-utility analysis based on the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial Eur Neuropsychopharmacol 23 1739-295
[10]
Pollock BG(2006)Ethical problems in pharmacogenetic studies of psychiatric disorders Pharmacogenomics J6 289-undefined